Trial Profile

First in-human trial of M102 in patients with the neurodegenerative disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Apr 2022 According to an Aclipse Therapeutics media release, the trial is expected to initiate in 2023
20 Apr 2022 According to an Aclipse Therapeutics media release, the Company has received a therapeutic development award from the Congressionally Directed Medical Research Programs at the United States Department of Defense's U.S. Army Medical Research and Development Command, as part of its FY21 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award. The award will fund development of M102 to Investigational New Drug (IND) Stage for Initiation of this trial.
08 Feb 2021 According to a University of Sheffield media release, the company has received research grant which will be used for this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com